According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for agomelatine tablets approved and issued by the State Drug Administration. The drug is a class of 4 chemicals with a specification of 25 mg. Clinically used to treat depression in adults, it is deemed to have passed the consistency evaluation. Up to now, the company has invested about 9.675 million yuan in R&D for this project. The drug was approved to expand the company's neurological drug product range. It will not have a significant impact on current business performance, and there is uncertainty about drug sales.

According to Sinopharm Hyundai's announcement, the company has received the “Drug Registration Certificate” for agomelatine tablets approved and issued by the State Drug Administration. The drug is a class of 4 chemicals with a specification of 25 mg. Clinically used to treat depression in adults, it is deemed to have passed the consistency evaluation. Up to now, the company has invested about 9.675 million yuan in R&D for this project. The drug was approved to expand the company's neurological drug product range. It will not have a significant impact on current business performance, and there is uncertainty about drug sales.